ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

This study is for people with a rare and aggressive type of lymphoma (peripheral T-cell lymphoma) that hasn't been treated yet. It compares standard chemotherapy alone to chemotherapy plus either duvelisib or CC-486, two drugs that may help stop cancer growth. The goal is to see …

This study was designed to see if adding tazemetostat to standard CHOP chemotherapy could improve outcomes for people with untreated peripheral T cell lymphoma. It was withdrawn before any participants enrolled, so no results are available. The goal was to increase the number of …

This early-phase trial tests whether combining two existing drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior therapy. About 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. T…

This study looks at whether giving vitamin D supplements to cancer patients who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 adults with certain types of lymphoma or leukemia are taking part. Researchers are comparing those who …

This study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…

This study tested a combination of a targeted drug (brentuximab vedotin) and chemotherapy in 48 people with a rare type of blood cancer called CD30-positive peripheral T-cell lymphoma. The goal was to see how well the treatment shrinks tumors and what side effects occur. Particip…

This early-stage trial tests a new treatment called WU-CART-007 for people with certain blood cancers (like acute myeloid leukemia and T-cell lymphoma) that have not responded to standard therapy. The treatment uses donor immune cells that are specially modified to target and kil…